View All News

Channelchek-in

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost. 

Access to Exclusive Content. FREE for Registered Users Only. 

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

Meta Platforms’ latest move to raise at least $25 billion in investment-grade bonds is more than just another mega-cap financing headline — it’s a signal that the next wave of growth in artificial intelligence and data infrastructure could trickle down to smaller tech players.



The offering — one of the largest U.S. corporate bond sales of 2025 — comes on the heels of Meta’s plan to ramp up spending on AI-driven products and infrastructure. With borrowing costs dropping as the Federal Reserve continues to cut rates, major tech firms are taking advantage of lower yields to finance a new round of capital expansion.



For small-cap technology companies, this could open the door to opportunity. The enormous amount of capital being deployed by hyperscalers like Meta, Microsoft, and Alphabet is creating a massive demand chain that extends far beyond Silicon Valley’s biggest names. Startups and smaller public firms involved in semiconductors, networking, data management, cooling systems, and cloud security are all potential beneficiaries as AI infrastructure scales up.



Meta’s $25 billion raise isn’t just about internal growth — it underscores a larger credit market trend that smaller firms can ride. With liquidity returning to corporate debt markets and investor appetite for yield still strong, smaller companies may find more favorable conditions to raise their own capital or secure partnerships with the giants driving AI expansion.



The implications are especially important for small-cap investors who have been cautious during a year of volatility. As large companies expand their data centers and AI capacity, many subcontractors and niche solution providers that feed into those ecosystems could see accelerated revenue growth. This includes firms building energy-efficient chips, AI integration tools, and hardware required to sustain hyperscale computing.



However, it’s not all upside. The aggressive pace of AI investment also raises the bar for innovation and speed. Smaller companies that fail to keep up with the capital intensity or technological demands of the space could struggle to compete. In addition, the market’s current enthusiasm for AI spending could make it harder for smaller firms to attract attention unless they’re directly tied to the sector’s most critical supply chains.



Still, Meta’s massive bond sale highlights how the AI arms race is influencing not just the tech giants but the broader investment landscape. For investors looking at small-cap stocks, the key is to identify which companies are poised to plug into the infrastructure boom — and which could be left behind as the giants keep scaling up.



As AI investment accelerates into 2026, this wave of corporate spending could prove to be a lifeline for small-cap tech companies, offering them both funding momentum and the potential for strategic partnerships with industry leaders.

Meta Platforms’ latest move to raise at least $25 billion in investment-grade bonds is more than just another mega-cap financing headline — it’s a signal that the next wave of growth in artificial intelligence and data infrastructure could trickle down to smaller tech players.



The offering — one of the largest U.S. corporate bond sales of 2025 — comes on the heels of Meta’s plan to ramp up spending on AI-driven products and infrastructure. With borrowing costs dropping as the Federal Reserve continues to cut rates, major tech firms are taking advantage of lower yields to finance a new round of capital expansion.



For small-cap technology companies, this could open the door to opportunity. The enormous amount of capital being deployed by hyperscalers like Meta, Microsoft, and Alphabet is creating a massive demand chain that extends far beyond Silicon Valley’s biggest names. Startups and smaller public firms involved in semiconductors, networking, data management, cooling systems, and cloud security are all potential beneficiaries as AI infrastructure scales up.



Meta’s $25 billion raise isn’t just about internal growth — it underscores a larger credit market trend that smaller firms can ride. With liquidity returning to corporate debt markets and investor appetite for yield still strong, smaller companies may find more favorable conditions to raise their own capital or secure partnerships with the giants driving AI expansion.



The implications are especially important for small-cap investors who have been cautious during a year of volatility. As large companies expand their data centers and AI capacity, many subcontractors and niche solution providers that feed into those ecosystems could see accelerated revenue growth. This includes firms building energy-efficient chips, AI integration tools, and hardware required to sustain hyperscale computing.



However, it’s not all upside. The aggressive pace of AI investment also raises the bar for innovation and speed. Smaller companies that fail to keep up with the capital intensity or technological demands of the space could struggle to compete. In addition, the market’s current enthusiasm for AI spending could make it harder for smaller firms to attract attention unless they’re directly tied to the sector’s most critical supply chains.



Still, Meta’s massive bond sale highlights how the AI arms race is influencing not just the tech giants but the broader investment landscape. For investors looking at small-cap stocks, the key is to identify which companies are poised to plug into the infrastructure boom — and which could be left behind as the giants keep scaling up.



As AI investment accelerates into 2026, this wave of corporate spending could prove to be a lifeline for small-cap tech companies, offering them both funding momentum and the potential for strategic partnerships with industry leaders.

Meta’s Massive Bond Sale Could Fuel a Ripple Effect for Small-Cap Tech Stocks

artificial intelligence

Bond Sale

Data centers

Tech

The Federal Reserve lowered interest rates for the second time this year on Wednesday, continuing its effort to stabilize the labor market amid rising unemployment concerns and an ongoing government data blackout.



Policymakers voted to reduce the benchmark federal funds rate by another quarter percentage point, setting a new range between 3.75% and 4% — the lowest level in three years. The move reflects the Fed’s cautious approach to balancing slowing job growth, stubborn inflation, and a murky economic outlook made worse by the shutdown of key government agencies.



For the first time in modern history, the Fed made a rate decision without access to a full month of official employment and inflation data. The lack of reliable government reports has complicated policymakers’ efforts to gauge the true health of the U.S. economy, particularly as layoffs from major employers like Amazon and Target signal that labor market conditions may be weakening.



The central bank began easing policy last month after private-sector data showed hiring had slowed to its weakest pace since 2010. Recent updates from payroll processors have indicated a slight rebound in hiring, though overall employment growth remains tepid. Without consistent data, the Fed is navigating largely in the dark, weighing the need to support jobs while keeping inflation contained.



<h3 class="wp-block-heading">Inflation and Tariffs Create Conflicting Signals</h3>



Inflation has cooled modestly in recent months, according to private data, but underlying price pressures remain. Businesses have managed to absorb higher costs tied to new tariffs rather than pass them directly to consumers, though economists warn that could change if trade tensions persist.



President Trump’s tariff policies, alongside shifting trade dynamics with China, continue to inject volatility into markets. The upcoming meeting between Trump and Chinese President Xi Jinping in South Korea could shape the trajectory of global trade and influence inflation expectations heading into 2026.



Despite these uncertainties, the Fed is signaling that its priority remains preventing a sharp rise in unemployment. The central bank’s rate cuts are designed to lower borrowing costs for businesses and consumers, encourage investment, and keep economic momentum intact as trade and political risks intensify.



In a separate announcement, the Fed confirmed that its three-year effort to reduce the size of its balance sheet will conclude by December 1. The portfolio — which peaked near $9 trillion in 2022 after the pandemic-era stimulus — has been trimmed to roughly $6.6 trillion, a level officials now view as closer to normal.



The move signals confidence that the financial system no longer requires extraordinary liquidity support, even as rate cuts continue.



For investors, the Fed’s latest cut underscores a cautious but proactive stance in navigating a fragile economic environment. Lower interest rates generally benefit equities, particularly small-cap stocks, which tend to be more sensitive to borrowing costs and domestic growth trends.



If the easing cycle continues, small-cap companies could see improved access to capital and renewed investor interest, especially in sectors like industrials, consumer goods, and technology — areas that often rebound first when monetary policy shifts dovish.



Still, with limited visibility into key economic indicators, volatility is likely to remain elevated in the weeks ahead. Market participants will be watching closely for updates on inflation, trade policy, and the labor market once government reporting resumes.

The Federal Reserve lowered interest rates for the second time this year on Wednesday, continuing its effort to stabilize the labor market amid rising unemployment concerns and an ongoing government data blackout.



Policymakers voted to reduce the benchmark federal funds rate by another quarter percentage point, setting a new range between 3.75% and 4% — the lowest level in three years. The move reflects the Fed’s cautious approach to balancing slowing job growth, stubborn inflation, and a murky economic outlook made worse by the shutdown of key government agencies.



For the first time in modern history, the Fed made a rate decision without access to a full month of official employment and inflation data. The lack of reliable government reports has complicated policymakers’ efforts to gauge the true health of the U.S. economy, particularly as layoffs from major employers like Amazon and Target signal that labor market conditions may be weakening.



The central bank began easing policy last month after private-sector data showed hiring had slowed to its weakest pace since 2010. Recent updates from payroll processors have indicated a slight rebound in hiring, though overall employment growth remains tepid. Without consistent data, the Fed is navigating largely in the dark, weighing the need to support jobs while keeping inflation contained.



Inflation and Tariffs Create Conflicting Signals



Inflation has cooled modestly in recent months, according to private data, but underlying price pressures remain. Businesses have managed to absorb higher costs tied to new tariffs rather than pass them directly to consumers, though economists warn that could change if trade tensions persist.



President Trump’s tariff policies, alongside shifting trade dynamics with China, continue to inject volatility into markets. The upcoming meeting between Trump and Chinese President Xi Jinping in South Korea could shape the trajectory of global trade and influence inflation expectations heading into 2026.



Despite these uncertainties, the Fed is signaling that its priority remains preventing a sharp rise in unemployment. The central bank’s rate cuts are designed to lower borrowing costs for businesses and consumers, encourage investment, and keep economic momentum intact as trade and political risks intensify.



In a separate announcement, the Fed confirmed that its three-year effort to reduce the size of its balance sheet will conclude by December 1. The portfolio — which peaked near $9 trillion in 2022 after the pandemic-era stimulus — has been trimmed to roughly $6.6 trillion, a level officials now view as closer to normal.



The move signals confidence that the financial system no longer requires extraordinary liquidity support, even as rate cuts continue.



For investors, the Fed’s latest cut underscores a cautious but proactive stance in navigating a fragile economic environment. Lower interest rates generally benefit equities, particularly small-cap stocks, which tend to be more sensitive to borrowing costs and domestic growth trends.



If the easing cycle continues, small-cap companies could see improved access to capital and renewed investor interest, especially in sectors like industrials, consumer goods, and technology — areas that often rebound first when monetary policy shifts dovish.



Still, with limited visibility into key economic indicators, volatility is likely to remain elevated in the weeks ahead. Market participants will be watching closely for updates on inflation, trade policy, and the labor market once government reporting resumes.

Fed’s Second Rate Cut Signals Shift in Economic Strategy — and Opens New Opportunities for Small Caps

Nvidia has officially become the first company in history to surpass a $5 trillion market capitalization, cementing its dominance in the artificial intelligence (AI) revolution and signaling a powerful shift in the global technology landscape. The company’s rise — powered by record demand for AI hardware and deep partnerships across industries — is sending ripple effects through the broader tech market, particularly among smaller players looking to capture their share of AI-driven growth.



The milestone, achieved after a 3.4% surge in Nvidia’s stock on Wednesday, underscores investor conviction in AI as a defining megatrend of the decade. Nvidia’s flagship GTC event amplified that momentum, featuring new collaborations across supercomputing, robotics, self-driving technology, pharmaceuticals, and 6G telecom infrastructure. These partnerships — spanning names like Uber, Palantir, Eli Lilly, and Oracle — showcase how deeply Nvidia’s technology is embedded in nearly every major industry.



But beyond the headline number, Nvidia’s success story holds significant implications for small-cap investors. As Nvidia scales its AI infrastructure globally, it creates massive downstream demand for smaller companies involved in the supply chain — from semiconductor component suppliers and circuit board manufacturers to cooling system specialists, data center builders, and power management innovators. Many of these firms trade in the small-cap space, where growth potential often accelerates once industry giants expand their spending.



For example, Nvidia’s partnership with the U.S. Department of Energy to build seven new supercomputers — including one powered by 10,000 Blackwell GPUs — will require a vast ecosystem of supporting technologies. Companies producing advanced materials, thermal management solutions, or even power delivery systems are poised to benefit as AI hardware capacity scales. This trickle-down effect is giving smaller, often under-the-radar players new relevance as key enablers of the AI revolution.



Recent comments from President Trump ahead of his meeting with Nvidia CEO Jensen Huang added further fuel to the rally, hinting at possible approval for new chip exports to China. While Nvidia itself stands to gain directly from a reopened Chinese market, many smaller semiconductor and logistics firms could see indirect benefits through increased trade volume and component demand.



At the same time, Nvidia’s rise to a $5 trillion valuation also highlights the widening gap between mega-cap leaders and emerging competitors. This dynamic often drives investors to seek opportunities among smaller, more agile firms that can innovate faster or serve niche markets overlooked by giants. Small-cap semiconductor developers, specialized software providers, and manufacturing partners could all capture new contracts as AI adoption accelerates across industries.



For small-cap investors, Nvidia’s historic milestone isn’t just a headline — it’s a signal. The company’s continued dominance validates AI’s long-term growth story, but it also points to a new wave of opportunity in the ecosystem surrounding it. Companies supplying energy-efficient chips, precision cooling systems, or automation technologies could become the next big winners as global demand for AI infrastructure scales beyond what even Nvidia can deliver alone.



As AI reshapes industries from finance to manufacturing, the small-cap space may once again become the breeding ground for the next generation of tech leaders — powered, in part, by the unprecedented rise of Nvidia.

Nvidia has officially become the first company in history to surpass a $5 trillion market capitalization, cementing its dominance in the artificial intelligence (AI) revolution and signaling a powerful shift in the global technology landscape. The company’s rise — powered by record demand for AI hardware and deep partnerships across industries — is sending ripple effects through the broader tech market, particularly among smaller players looking to capture their share of AI-driven growth.



The milestone, achieved after a 3.4% surge in Nvidia’s stock on Wednesday, underscores investor conviction in AI as a defining megatrend of the decade. Nvidia’s flagship GTC event amplified that momentum, featuring new collaborations across supercomputing, robotics, self-driving technology, pharmaceuticals, and 6G telecom infrastructure. These partnerships — spanning names like Uber, Palantir, Eli Lilly, and Oracle — showcase how deeply Nvidia’s technology is embedded in nearly every major industry.



But beyond the headline number, Nvidia’s success story holds significant implications for small-cap investors. As Nvidia scales its AI infrastructure globally, it creates massive downstream demand for smaller companies involved in the supply chain — from semiconductor component suppliers and circuit board manufacturers to cooling system specialists, data center builders, and power management innovators. Many of these firms trade in the small-cap space, where growth potential often accelerates once industry giants expand their spending.



For example, Nvidia’s partnership with the U.S. Department of Energy to build seven new supercomputers — including one powered by 10,000 Blackwell GPUs — will require a vast ecosystem of supporting technologies. Companies producing advanced materials, thermal management solutions, or even power delivery systems are poised to benefit as AI hardware capacity scales. This trickle-down effect is giving smaller, often under-the-radar players new relevance as key enablers of the AI revolution.



Recent comments from President Trump ahead of his meeting with Nvidia CEO Jensen Huang added further fuel to the rally, hinting at possible approval for new chip exports to China. While Nvidia itself stands to gain directly from a reopened Chinese market, many smaller semiconductor and logistics firms could see indirect benefits through increased trade volume and component demand.



At the same time, Nvidia’s rise to a $5 trillion valuation also highlights the widening gap between mega-cap leaders and emerging competitors. This dynamic often drives investors to seek opportunities among smaller, more agile firms that can innovate faster or serve niche markets overlooked by giants. Small-cap semiconductor developers, specialized software providers, and manufacturing partners could all capture new contracts as AI adoption accelerates across industries.



For small-cap investors, Nvidia’s historic milestone isn’t just a headline — it’s a signal. The company’s continued dominance validates AI’s long-term growth story, but it also points to a new wave of opportunity in the ecosystem surrounding it. Companies supplying energy-efficient chips, precision cooling systems, or automation technologies could become the next big winners as global demand for AI infrastructure scales beyond what even Nvidia can deliver alone.



As AI reshapes industries from finance to manufacturing, the small-cap space may once again become the breeding ground for the next generation of tech leaders — powered, in part, by the unprecedented rise of Nvidia.

Nvidia Becomes World’s First $5 Trillion Company, Fueling Broader AI Sector Momentum

Jensen Huang

Nvidia

Semiconductors

Noble Capital Markets Research Morning Call

U.S. consumer confidence continued to weaken in October, marking the third straight month of decline as Americans grew increasingly concerned about inflation, employment prospects, and overall economic conditions.



According to the latest survey from The Conference Board, the Consumer Confidence Index slipped to 94.6, its lowest reading since April 2025. While consumers’ perception of current business and labor conditions showed modest improvement, their short-term outlook for income, job availability, and business conditions deteriorated further.



Economists note that this steady decline reflects a mix of economic pressures — from persistent inflation to lingering uncertainty about tariffs and job stability. The index’s expectations component, which tracks consumers’ six-month outlook, dropped nearly three points in October, remaining below levels that historically signal the early stages of a recession.



Confidence also continues to diverge sharply among income groups, underscoring the “K-shaped” nature of the current recovery — where higher-income households remain relatively resilient while lower-income families struggle with rising costs.



While consumers have become slightly more positive about current job opportunities, optimism about the future has waned. Only 15.8% of respondents expect more jobs to be available in the next six months, down from 16.6% in September. Meanwhile, the share of Americans anticipating higher incomes edged lower, suggesting households are tightening budgets in anticipation of slower wage growth and elevated living costs.



Private labor data paints a mixed picture. Payroll processor ADP reported that hiring showed a “tepid recovery” in October, with gains concentrated in healthcare and services. However, these figures come amid a backdrop of high-profile layoffs at major companies such as Amazon and UPS, fueling concerns that corporate cost-cutting could spread across industries as growth slows.



Adding to the uncertainty, the ongoing federal government shutdown has delayed key economic reports, including the September and October employment data. Analysts warn that policymakers and investors are operating with limited visibility into real-time economic trends, complicating efforts to gauge the true strength of the U.S. economy.



Despite these challenges, inflation data released late last week offered a modestly positive note. Prices rose at a slightly slower pace in September than expected, suggesting that some cost pressures may be easing — though not enough to offset broader consumer unease.



For investors, the decline in consumer confidence highlights growing caution in the marketplace. Lower sentiment often translates into weaker consumer spending — a critical driver of U.S. GDP — and can weigh on earnings across sectors like retail, travel, and discretionary goods. On the other hand, cooling demand could strengthen the case for another Federal Reserve rate cut later this year, potentially supporting equities and credit markets in the short term.



Overall, the October data underscores a cautious economic landscape where optimism is fading and the outlook remains clouded by inflation, job uncertainty, and political gridlock. Whether confidence stabilizes or continues to slide will depend largely on how quickly inflation eases and job growth resumes in the months ahead.

U.S. consumer confidence continued to weaken in October, marking the third straight month of decline as Americans grew increasingly concerned about inflation, employment prospects, and overall economic conditions.



According to the latest survey from The Conference Board, the Consumer Confidence Index slipped to 94.6, its lowest reading since April 2025. While consumers’ perception of current business and labor conditions showed modest improvement, their short-term outlook for income, job availability, and business conditions deteriorated further.



Economists note that this steady decline reflects a mix of economic pressures — from persistent inflation to lingering uncertainty about tariffs and job stability. The index’s expectations component, which tracks consumers’ six-month outlook, dropped nearly three points in October, remaining below levels that historically signal the early stages of a recession.



Confidence also continues to diverge sharply among income groups, underscoring the “K-shaped” nature of the current recovery — where higher-income households remain relatively resilient while lower-income families struggle with rising costs.



While consumers have become slightly more positive about current job opportunities, optimism about the future has waned. Only 15.8% of respondents expect more jobs to be available in the next six months, down from 16.6% in September. Meanwhile, the share of Americans anticipating higher incomes edged lower, suggesting households are tightening budgets in anticipation of slower wage growth and elevated living costs.



Private labor data paints a mixed picture. Payroll processor ADP reported that hiring showed a “tepid recovery” in October, with gains concentrated in healthcare and services. However, these figures come amid a backdrop of high-profile layoffs at major companies such as Amazon and UPS, fueling concerns that corporate cost-cutting could spread across industries as growth slows.



Adding to the uncertainty, the ongoing federal government shutdown has delayed key economic reports, including the September and October employment data. Analysts warn that policymakers and investors are operating with limited visibility into real-time economic trends, complicating efforts to gauge the true strength of the U.S. economy.



Despite these challenges, inflation data released late last week offered a modestly positive note. Prices rose at a slightly slower pace in September than expected, suggesting that some cost pressures may be easing — though not enough to offset broader consumer unease.



For investors, the decline in consumer confidence highlights growing caution in the marketplace. Lower sentiment often translates into weaker consumer spending — a critical driver of U.S. GDP — and can weigh on earnings across sectors like retail, travel, and discretionary goods. On the other hand, cooling demand could strengthen the case for another Federal Reserve rate cut later this year, potentially supporting equities and credit markets in the short term.



Overall, the October data underscores a cautious economic landscape where optimism is fading and the outlook remains clouded by inflation, job uncertainty, and political gridlock. Whether confidence stabilizes or continues to slide will depend largely on how quickly inflation eases and job growth resumes in the months ahead.

Consumer Confidence Slips Again as Americans Brace for Higher Prices and Fewer Jobs

Apple has once again proven its staying power in the global tech landscape, briefly touching a $4 trillion market capitalization before pulling back slightly. The milestone underscores renewed investor optimism as strong early sales of the new iPhone 17 lineup signal that Apple’s growth engine remains alive and well.



According to data from Counterpoint Research, the iPhone 17 series outperformed its predecessor, the iPhone 16, during its first 10 days of release in both the U.S. and China—two of Apple’s most important markets. Year over year, iPhone sales surged 14%, with the base iPhone 17 and high-end iPhone 17 Pro drawing the most attention from consumers. The newly introduced iPhone Air also saw solid momentum, slightly outselling the discontinued iPhone Plus.



Apple’s stock climbed on the back of these strong figures, propelling its valuation into the $4 trillion club alongside fellow tech giants Nvidia and Microsoft. While Apple has flirted with this threshold before, the combination of resilient hardware demand and ongoing investor confidence helped push it back into record territory.



Still, not all analysts are convinced the sales surge will hold steady. Recent tracking from Jefferies suggests iPhone demand may be cooling slightly week over week, with delivery lead times shortening across major markets. In the U.S. and Europe, the once-long waits for iPhone 17 Pro and Pro Max models have largely disappeared, hinting that initial supply bottlenecks have eased.



Even so, Apple’s iPhone remains its crown jewel. The device generated $201.2 billion in revenue in 2024, more than half of the company’s total $391 billion. Its Services segment—covering everything from Apple TV+ to iCloud—added another $96.2 billion, showcasing the company’s ability to diversify beyond hardware.



Unlike Nvidia and Microsoft, whose valuations have surged on the strength of artificial intelligence development, Apple has taken a more measured approach. The company has yet to unveil its long-awaited AI-powered version of Siri, even as competitors like Google and Samsung continue to push forward with AI-enhanced products such as Gemini and Galaxy AI.



Despite that, Apple’s ecosystem remains unmatched. With over one billion active iPhones worldwide, along with a growing base of Apple Watch, AirPods, and service subscribers, the company benefits from an unparalleled level of customer loyalty. Each product launch not only drives revenue but reinforces a network of users deeply embedded in Apple’s ecosystem.



For investors, the story is clear: Apple may not be leading the AI revolution—yet—but its scale, cash flow, and brand strength continue to make it one of the most dependable growth stories in global markets. The $4 trillion mark is less about a temporary milestone and more about a company that continues to define what long-term market dominance looks like.

Apple has once again proven its staying power in the global tech landscape, briefly touching a $4 trillion market capitalization before pulling back slightly. The milestone underscores renewed investor optimism as strong early sales of the new iPhone 17 lineup signal that Apple’s growth engine remains alive and well.



According to data from Counterpoint Research, the iPhone 17 series outperformed its predecessor, the iPhone 16, during its first 10 days of release in both the U.S. and China—two of Apple’s most important markets. Year over year, iPhone sales surged 14%, with the base iPhone 17 and high-end iPhone 17 Pro drawing the most attention from consumers. The newly introduced iPhone Air also saw solid momentum, slightly outselling the discontinued iPhone Plus.



Apple’s stock climbed on the back of these strong figures, propelling its valuation into the $4 trillion club alongside fellow tech giants Nvidia and Microsoft. While Apple has flirted with this threshold before, the combination of resilient hardware demand and ongoing investor confidence helped push it back into record territory.



Still, not all analysts are convinced the sales surge will hold steady. Recent tracking from Jefferies suggests iPhone demand may be cooling slightly week over week, with delivery lead times shortening across major markets. In the U.S. and Europe, the once-long waits for iPhone 17 Pro and Pro Max models have largely disappeared, hinting that initial supply bottlenecks have eased.



Even so, Apple’s iPhone remains its crown jewel. The device generated $201.2 billion in revenue in 2024, more than half of the company’s total $391 billion. Its Services segment—covering everything from Apple TV+ to iCloud—added another $96.2 billion, showcasing the company’s ability to diversify beyond hardware.



Unlike Nvidia and Microsoft, whose valuations have surged on the strength of artificial intelligence development, Apple has taken a more measured approach. The company has yet to unveil its long-awaited AI-powered version of Siri, even as competitors like Google and Samsung continue to push forward with AI-enhanced products such as Gemini and Galaxy AI.



Despite that, Apple’s ecosystem remains unmatched. With over one billion active iPhones worldwide, along with a growing base of Apple Watch, AirPods, and service subscribers, the company benefits from an unparalleled level of customer loyalty. Each product launch not only drives revenue but reinforces a network of users deeply embedded in Apple’s ecosystem.



For investors, the story is clear: Apple may not be leading the AI revolution—yet—but its scale, cash flow, and brand strength continue to make it one of the most dependable growth stories in global markets. The $4 trillion mark is less about a temporary milestone and more about a company that continues to define what long-term market dominance looks like.

Apple Hits $4 Trillion Milestone as iPhone 17 Sales Power Market Momentum

AAPL

Apple

Technology

The Federal Reserve is expected to lower interest rates again this week, even as policymakers navigate an unusually uncertain environment caused by the ongoing government shutdown. With most official economic data unavailable since early October, central bank officials are relying on private-sector reports and anecdotal evidence to guide their decision-making.



This marks the second rate cut of 2025, as the Fed continues to balance the dual challenges of cooling inflation and a weakening job market. The shutdown, which began on October 1, has halted the release of key reports, including the monthly jobs data that typically plays a pivotal role in shaping monetary policy. In the absence of those figures, alternative data sources from payroll processors and research firms suggest that hiring has slowed sharply, pointing to potential cracks in the labor market.



Private-sector reports indicate that U.S. employers reduced jobs in September, marking a significant shift from the steady gains earlier in the year. Sectors like healthcare continue to add positions, but most other areas — including manufacturing, construction, and retail — are showing signs of contraction. Economists believe this slowdown reflects weaker demand rather than a shortage of available workers, signaling that the broader economy may be cooling more rapidly than anticipated.



Adding to the complexity, inflation data remains mixed. The Consumer Price Index showed a slight decline in September, with core inflation rising 3% year over year, down from 3.1% the month prior. While the moderation in prices provides some relief, inflation still sits above the Fed’s 2% target. Economists warn that new tariffs and rising consumer costs could keep price pressures elevated in the months ahead, making it harder for policymakers to strike the right balance.



The Fed’s dilemma is compounded by growing signs of financial strain in certain lending markets. Losses in subprime auto loans and stress in commercial lending have raised concerns about the overall health of the financial system. While analysts don’t view these issues as systemic, they consider them early indicators that consumers and smaller banks are under pressure as growth slows.



Despite these warning signs, most analysts expect the Federal Open Market Committee (FOMC) to approve a 0.25% rate cut this week, bringing borrowing costs further down as part of a broader effort to support the labor market. Markets have already priced in another possible cut before year’s end, though the timing and extent of future moves will likely depend on when official government data becomes available again.



Fed Chair Jerome Powell has acknowledged that the lack of reliable data leaves policymakers in a difficult position, forcing them to rely on partial information and economic models to assess risks. With inflation easing slightly but employment softening, the central bank appears committed to erring on the side of supporting growth — even if that means acting with limited visibility.



The path ahead remains uncertain. If inflation stabilizes and job losses accelerate, the Fed may continue cutting rates into early 2026. But if inflation proves more persistent than expected, the central bank could be forced to pause its easing cycle sooner than markets anticipate. Either way, the current data blackout underscores how fragile the economic landscape remains — and how challenging it is for the Fed to steer policy when flying blind.

The Federal Reserve is expected to lower interest rates again this week, even as policymakers navigate an unusually uncertain environment caused by the ongoing government shutdown. With most official economic data unavailable since early October, central bank officials are relying on private-sector reports and anecdotal evidence to guide their decision-making.



This marks the second rate cut of 2025, as the Fed continues to balance the dual challenges of cooling inflation and a weakening job market. The shutdown, which began on October 1, has halted the release of key reports, including the monthly jobs data that typically plays a pivotal role in shaping monetary policy. In the absence of those figures, alternative data sources from payroll processors and research firms suggest that hiring has slowed sharply, pointing to potential cracks in the labor market.



Private-sector reports indicate that U.S. employers reduced jobs in September, marking a significant shift from the steady gains earlier in the year. Sectors like healthcare continue to add positions, but most other areas — including manufacturing, construction, and retail — are showing signs of contraction. Economists believe this slowdown reflects weaker demand rather than a shortage of available workers, signaling that the broader economy may be cooling more rapidly than anticipated.



Adding to the complexity, inflation data remains mixed. The Consumer Price Index showed a slight decline in September, with core inflation rising 3% year over year, down from 3.1% the month prior. While the moderation in prices provides some relief, inflation still sits above the Fed’s 2% target. Economists warn that new tariffs and rising consumer costs could keep price pressures elevated in the months ahead, making it harder for policymakers to strike the right balance.



The Fed’s dilemma is compounded by growing signs of financial strain in certain lending markets. Losses in subprime auto loans and stress in commercial lending have raised concerns about the overall health of the financial system. While analysts don’t view these issues as systemic, they consider them early indicators that consumers and smaller banks are under pressure as growth slows.



Despite these warning signs, most analysts expect the Federal Open Market Committee (FOMC) to approve a 0.25% rate cut this week, bringing borrowing costs further down as part of a broader effort to support the labor market. Markets have already priced in another possible cut before year’s end, though the timing and extent of future moves will likely depend on when official government data becomes available again.



Fed Chair Jerome Powell has acknowledged that the lack of reliable data leaves policymakers in a difficult position, forcing them to rely on partial information and economic models to assess risks. With inflation easing slightly but employment softening, the central bank appears committed to erring on the side of supporting growth — even if that means acting with limited visibility.



The path ahead remains uncertain. If inflation stabilizes and job losses accelerate, the Fed may continue cutting rates into early 2026. But if inflation proves more persistent than expected, the central bank could be forced to pause its easing cycle sooner than markets anticipate. Either way, the current data blackout underscores how fragile the economic landscape remains — and how challenging it is for the Fed to steer policy when flying blind.

Fed Poised to Cut Interest Rates Again Despite Data Blackout Amid Government Shutdown

Federal Reserve

Government Shutdown

Interest RAtes

Rate Cuts

Swiss pharmaceutical giant Novartis AG announced plans to acquire Avidity Biosciences for approximately $12 billion in cash, a move aimed at deepening its focus on rare and neuromuscular diseases while navigating an increasingly complex U.S. trade and regulatory landscape.



Under the terms of the agreement, Avidity shareholders will receive $72 per share, representing a 46% premium to the company’s most recent closing price. The acquisition, expected to close later this year pending regulatory approval, underscores Novartis’ aggressive strategy to expand its biotech capabilities and offset upcoming patent expirations on several of its blockbuster therapies.



The deal also includes the formation of a new spin-off company, Spinco, which will house Avidity’s early-stage precision cardiology programs. Spinco is expected to operate as an independent, publicly traded firm, led by Avidity’s current Chief Program Officer, Kathleen Gallagher.



Headquartered in San Diego, Avidity Biosciences has gained attention for pioneering a new class of RNA-based therapeutics that directly target muscle tissue. Its lead candidate, Del-zota, is being developed to treat a rare subtype of Duchenne muscular dystrophy (DMD), a debilitating genetic disorder that leads to progressive muscle weakness. Avidity is also advancing two other promising treatments for serious neuromuscular diseases, all of which leverage its proprietary antibody oligonucleotide conjugate (AOC) platform.



For Novartis, this acquisition offers a timely expansion into rare disease treatments — a sector experiencing growing investor interest due to high unmet medical needs and favorable regulatory incentives. The move is consistent with Novartis’ 2024 acquisition of Kate Therapeutics, another biotech developing gene therapies for muscle diseases, as well as its 2025 deals with Anthos Therapeutics and Regulus Therapeutics, collectively strengthening its position in genetic and cardiovascular medicine.



The rare disease market has become an increasingly competitive frontier for pharmaceutical innovation. Analysts note that Novartis’ acquisition spree is partly driven by its looming patent cliff, as flagship drugs such as Entresto, Xolair, and Cosentyx approach the end of their exclusivity periods. By acquiring companies like Avidity, Novartis not only diversifies its revenue base but also positions itself at the forefront of next-generation therapeutics that could define the next decade of biotech innovation.



The acquisition also carries strategic geopolitical undertones. With the Trump administration imposing 39% tariffs on Switzerland earlier this year, Swiss-based pharmaceutical companies face heightened uncertainty over U.S. trade policy. Expanding operations through American biotech acquisitions helps Novartis maintain a strong U.S. presence and mitigate risks tied to international tariffs.



For small-cap investors, the transaction reinforces an ongoing trend in the life sciences sector: large-cap pharma companies are increasingly looking to buy innovation rather than build it in-house. Early-stage biotech firms with validated technologies, particularly in RNA, gene therapy, and rare disease research, continue to attract premium valuations in acquisition deals.



Ultimately, Novartis’ acquisition of Avidity Biosciences is more than just a growth strategy — it’s a signal of where the pharmaceutical industry is heading. With advances in RNA therapeutics and genetic medicine accelerating, investors can expect more high-value takeovers in the months ahead as established players race to secure the next generation of life-changing treatments.

Swiss pharmaceutical giant Novartis AG announced plans to acquire Avidity Biosciences for approximately $12 billion in cash, a move aimed at deepening its focus on rare and neuromuscular diseases while navigating an increasingly complex U.S. trade and regulatory landscape.



Under the terms of the agreement, Avidity shareholders will receive $72 per share, representing a 46% premium to the company’s most recent closing price. The acquisition, expected to close later this year pending regulatory approval, underscores Novartis’ aggressive strategy to expand its biotech capabilities and offset upcoming patent expirations on several of its blockbuster therapies.



The deal also includes the formation of a new spin-off company, Spinco, which will house Avidity’s early-stage precision cardiology programs. Spinco is expected to operate as an independent, publicly traded firm, led by Avidity’s current Chief Program Officer, Kathleen Gallagher.



Headquartered in San Diego, Avidity Biosciences has gained attention for pioneering a new class of RNA-based therapeutics that directly target muscle tissue. Its lead candidate, Del-zota, is being developed to treat a rare subtype of Duchenne muscular dystrophy (DMD), a debilitating genetic disorder that leads to progressive muscle weakness. Avidity is also advancing two other promising treatments for serious neuromuscular diseases, all of which leverage its proprietary antibody oligonucleotide conjugate (AOC) platform.



For Novartis, this acquisition offers a timely expansion into rare disease treatments — a sector experiencing growing investor interest due to high unmet medical needs and favorable regulatory incentives. The move is consistent with Novartis’ 2024 acquisition of Kate Therapeutics, another biotech developing gene therapies for muscle diseases, as well as its 2025 deals with Anthos Therapeutics and Regulus Therapeutics, collectively strengthening its position in genetic and cardiovascular medicine.



The rare disease market has become an increasingly competitive frontier for pharmaceutical innovation. Analysts note that Novartis’ acquisition spree is partly driven by its looming patent cliff, as flagship drugs such as Entresto, Xolair, and Cosentyx approach the end of their exclusivity periods. By acquiring companies like Avidity, Novartis not only diversifies its revenue base but also positions itself at the forefront of next-generation therapeutics that could define the next decade of biotech innovation.



The acquisition also carries strategic geopolitical undertones. With the Trump administration imposing 39% tariffs on Switzerland earlier this year, Swiss-based pharmaceutical companies face heightened uncertainty over U.S. trade policy. Expanding operations through American biotech acquisitions helps Novartis maintain a strong U.S. presence and mitigate risks tied to international tariffs.



For small-cap investors, the transaction reinforces an ongoing trend in the life sciences sector: large-cap pharma companies are increasingly looking to buy innovation rather than build it in-house. Early-stage biotech firms with validated technologies, particularly in RNA, gene therapy, and rare disease research, continue to attract premium valuations in acquisition deals.



Ultimately, Novartis’ acquisition of Avidity Biosciences is more than just a growth strategy — it’s a signal of where the pharmaceutical industry is heading. With advances in RNA therapeutics and genetic medicine accelerating, investors can expect more high-value takeovers in the months ahead as established players race to secure the next generation of life-changing treatments.

Novartis’ $12 Billion Avidity Acquisition Strengthens Its Rare Disease Pipeline Amid Pharma Tariff Uncertainty

Avidity

Biotech

Gene Therapy

M&amp;A

Novartis

Inflation eased slightly in September, coming in below economists’ expectations and offering fresh signs that price pressures may be gradually cooling. The latest Consumer Price Index (CPI) report showed prices rising 3% year-over-year, just below the 3.1% forecast, and up 0.3% from August. While inflation remains above the Federal Reserve’s 2% target, investors took the softer reading as confirmation that the Fed is likely to move forward with a quarter-point rate cut at its upcoming meeting.



For small-cap investors, this development could be particularly meaningful. Lower interest rates often translate to cheaper borrowing costs, which can provide a boost to smaller, growth-oriented companies that rely more heavily on credit to fund operations and expansion. In contrast to large-cap corporations with stronger balance sheets, small caps tend to feel monetary shifts more directly — both on the upside and downside.



The report also showed encouraging moderation in key components. Core inflation, which excludes volatile food and energy prices, rose 3% year-over-year, slightly cooler than August’s 3.1%. Meanwhile, shelter costs — one of the stickiest contributors to inflation — increased only 0.2% month-over-month, the smallest gain in over two years. Housing and rent data are often lagging indicators, so any sustained cooling there could accelerate broader disinflation trends heading into the new year.



Still, the data wasn’t uniformly positive. Gasoline prices spiked 4.1% in September, driven by higher crude costs and seasonal demand, while apparel and household furnishings also saw noticeable increases. Yet overall, the direction of inflation remains encouraging for equity markets, particularly for rate-sensitive sectors such as small caps, regional banks, and industrials.



Another notable element of this report is the timing. Released amid a prolonged government shutdown, this CPI print is expected to be one of the last reliable economic data points for several months. Economists warn that future readings may rely more heavily on estimates, increasing uncertainty. That backdrop could heighten market volatility — but for investors with a long-term focus, it may also create tactical opportunities in undervalued areas of the market.



Historically, periods of easing inflation paired with falling interest rates have favored small-cap performance relative to large-cap benchmarks. The Russell 2000, for example, has outperformed the S&amp;P 500 during early-stage easing cycles in more than 70% of past Fed transitions. With inflation holding near 3% and rate cuts on the horizon, investors may soon see renewed rotation into smaller, domestically focused companies — especially those positioned to benefit from lower financing costs and rising consumer spending.



While it’s still too early to declare victory over inflation, September’s CPI data supports the narrative of a “soft landing” — an environment where growth slows without tipping into recession. If that holds, small caps could emerge as one of the biggest beneficiaries in the coming months, offering renewed potential for outsized returns as markets adjust to a lower-rate landscape.

Inflation eased slightly in September, coming in below economists’ expectations and offering fresh signs that price pressures may be gradually cooling. The latest Consumer Price Index (CPI) report showed prices rising 3% year-over-year, just below the 3.1% forecast, and up 0.3% from August. While inflation remains above the Federal Reserve’s 2% target, investors took the softer reading as confirmation that the Fed is likely to move forward with a quarter-point rate cut at its upcoming meeting.



For small-cap investors, this development could be particularly meaningful. Lower interest rates often translate to cheaper borrowing costs, which can provide a boost to smaller, growth-oriented companies that rely more heavily on credit to fund operations and expansion. In contrast to large-cap corporations with stronger balance sheets, small caps tend to feel monetary shifts more directly — both on the upside and downside.



The report also showed encouraging moderation in key components. Core inflation, which excludes volatile food and energy prices, rose 3% year-over-year, slightly cooler than August’s 3.1%. Meanwhile, shelter costs — one of the stickiest contributors to inflation — increased only 0.2% month-over-month, the smallest gain in over two years. Housing and rent data are often lagging indicators, so any sustained cooling there could accelerate broader disinflation trends heading into the new year.



Still, the data wasn’t uniformly positive. Gasoline prices spiked 4.1% in September, driven by higher crude costs and seasonal demand, while apparel and household furnishings also saw noticeable increases. Yet overall, the direction of inflation remains encouraging for equity markets, particularly for rate-sensitive sectors such as small caps, regional banks, and industrials.



Another notable element of this report is the timing. Released amid a prolonged government shutdown, this CPI print is expected to be one of the last reliable economic data points for several months. Economists warn that future readings may rely more heavily on estimates, increasing uncertainty. That backdrop could heighten market volatility — but for investors with a long-term focus, it may also create tactical opportunities in undervalued areas of the market.



Historically, periods of easing inflation paired with falling interest rates have favored small-cap performance relative to large-cap benchmarks. The Russell 2000, for example, has outperformed the S&amp;P 500 during early-stage easing cycles in more than 70% of past Fed transitions. With inflation holding near 3% and rate cuts on the horizon, investors may soon see renewed rotation into smaller, domestically focused companies — especially those positioned to benefit from lower financing costs and rising consumer spending.



While it’s still too early to declare victory over inflation, September’s CPI data supports the narrative of a “soft landing” — an environment where growth slows without tipping into recession. If that holds, small caps could emerge as one of the biggest beneficiaries in the coming months, offering renewed potential for outsized returns as markets adjust to a lower-rate landscape.

Cooling Inflation Keeps Fed on Track for Rate Cut

Inlfation

Soft Landing

Eli Lilly and Company’s agreement to acquire Adverum Biotechnologies marks another major move in the race to dominate the emerging field of genetic medicine. The deal, announced Friday, highlights the pharmaceutical giant’s commitment to expanding its gene therapy portfolio and targeting treatments that address chronic, age-related diseases — a market expected to grow rapidly over the next decade.



Under the terms of the agreement, Lilly will acquire all outstanding shares of Adverum for $3.56 per share in cash, plus a contingent value right (CVR) worth up to an additional $8.91 per share, depending on key regulatory and sales milestones. This brings the potential total value of the transaction to $12.47 per share. The deal is expected to close by the fourth quarter of 2025, pending shareholder and regulatory approval.



Adverum’s leading asset, Ixo-vec, is a one-time intravitreal gene therapy in Phase 3 development for wet age-related macular degeneration (wAMD) — a progressive retinal condition that affects millions of older adults worldwide. The therapy aims to reduce the need for repeated eye injections by delivering long-term aflibercept production directly within the eye. If successful, Ixo-vec could reshape the standard of care for patients who currently rely on frequent treatments to preserve vision.



The acquisition aligns with Lilly’s broader strategy of integrating genetic medicine technologies into its drug discovery pipeline. The company has already made significant investments in obesity, diabetes, and Alzheimer’s research, and sees gene therapy as a natural extension of that work. By adding Adverum’s proprietary intravitreal delivery platform and its promising ocular gene therapy programs, Lilly gains both innovation and market access in a field expected to see accelerating demand.



From a financial standpoint, the structure of the deal — combining upfront cash with milestone-based CVRs — reflects a balanced approach to managing risk while still rewarding Adverum shareholders if Ixo-vec achieves commercial success. The program’s FDA Fast Track and RMAT designations, as well as PRIME status from the European Medicines Agency, signal strong regulatory support and potential for expedited approval.



The move also underscores a broader trend across the biotech industry: large-cap pharmaceutical companies are increasingly acquiring smaller clinical-stage firms to secure access to cutting-edge gene therapy pipelines. For small-cap investors, this represents an important theme — as emerging biotech companies with late-stage assets become prime takeover targets in the current market cycle.



Gene therapy remains one of the most promising and competitive frontiers in modern medicine. While challenges such as manufacturing scale and long-term efficacy remain, the science continues to mature rapidly. Lilly’s acquisition of Adverum not only validates the commercial potential of ocular gene therapies but also signals continued confidence in the sector’s long-term growth trajectory.



If Ixo-vec succeeds, it could open the door to broader applications of gene therapy across multiple chronic conditions — reinforcing the idea that “one and done” treatments may soon become reality for millions of patients worldwide.

Eli Lilly and Company’s agreement to acquire Adverum Biotechnologies marks another major move in the race to dominate the emerging field of genetic medicine. The deal, announced Friday, highlights the pharmaceutical giant’s commitment to expanding its gene therapy portfolio and targeting treatments that address chronic, age-related diseases — a market expected to grow rapidly over the next decade.



Under the terms of the agreement, Lilly will acquire all outstanding shares of Adverum for $3.56 per share in cash, plus a contingent value right (CVR) worth up to an additional $8.91 per share, depending on key regulatory and sales milestones. This brings the potential total value of the transaction to $12.47 per share. The deal is expected to close by the fourth quarter of 2025, pending shareholder and regulatory approval.



Adverum’s leading asset, Ixo-vec, is a one-time intravitreal gene therapy in Phase 3 development for wet age-related macular degeneration (wAMD) — a progressive retinal condition that affects millions of older adults worldwide. The therapy aims to reduce the need for repeated eye injections by delivering long-term aflibercept production directly within the eye. If successful, Ixo-vec could reshape the standard of care for patients who currently rely on frequent treatments to preserve vision.



The acquisition aligns with Lilly’s broader strategy of integrating genetic medicine technologies into its drug discovery pipeline. The company has already made significant investments in obesity, diabetes, and Alzheimer’s research, and sees gene therapy as a natural extension of that work. By adding Adverum’s proprietary intravitreal delivery platform and its promising ocular gene therapy programs, Lilly gains both innovation and market access in a field expected to see accelerating demand.



From a financial standpoint, the structure of the deal — combining upfront cash with milestone-based CVRs — reflects a balanced approach to managing risk while still rewarding Adverum shareholders if Ixo-vec achieves commercial success. The program’s FDA Fast Track and RMAT designations, as well as PRIME status from the European Medicines Agency, signal strong regulatory support and potential for expedited approval.



The move also underscores a broader trend across the biotech industry: large-cap pharmaceutical companies are increasingly acquiring smaller clinical-stage firms to secure access to cutting-edge gene therapy pipelines. For small-cap investors, this represents an important theme — as emerging biotech companies with late-stage assets become prime takeover targets in the current market cycle.



Gene therapy remains one of the most promising and competitive frontiers in modern medicine. While challenges such as manufacturing scale and long-term efficacy remain, the science continues to mature rapidly. Lilly’s acquisition of Adverum not only validates the commercial potential of ocular gene therapies but also signals continued confidence in the sector’s long-term growth trajectory.



If Ixo-vec succeeds, it could open the door to broader applications of gene therapy across multiple chronic conditions — reinforcing the idea that “one and done” treatments may soon become reality for millions of patients worldwide.

Lilly’s Adverum Acquisition Signals Growing Appetite for Gene Therapy Investments

Footer menu

Contact Me

Feedback

Test form

Event Registration

The NobleCon20 VIP Giveaway

Noble Announcement | 2H 2025 Events

Main menu

The NobleCon20 VIP Giveaway – Terms and Conditions
1. Organizer The NobleCon20 VIP Giveaway (“Contest”) is organized by Noble Financial Group and Channelchek (“Organizers”).
2. Eligibility The Contest is open to legal residents of the United States who are 18 years of age or older at the time of entry. Employees of the Organizers, their affiliates, subsidiaries, advertising and promotion agencies, and immediate family members are not eligible to participate.
3. Contest Period The Contest begins on [Start Date] and ends on October 31, 2024, at 11:59 PM ET. Entries submitted after the Contest Period will not be considered.
4. How to Enter To enter the Contest:
<ul>
<li>You must be a registered and verified Channelchek member.</li>
<li>You must complete the Contest entry form available at [Entry Form URL].</li>
</ul>
5. Prize The prize package includes:
<ul>
<li>Round-trip economy airfare for two (2) to South Florida to attend NobleCon20.</li>
<li>Two (2) hotel rooms for the duration of NobleCon20.</li>
<li>Two (2) tickets to NobleCon20, including access to all official NobleCon20 events.</li>
<li>Two (2) VIP meet-and-greet upgrades to the headline event featuring three (3) of the Sharks from ABC’s Shark Tank.</li>
</ul>
There will be one (1) winner chosen. All travel and accommodations are subject to availability and must be arranged through the Organizers. No substitution, transfer, or cash equivalent of prizes is permitted.
6. Winner Selection The winner will be selected on November 1, 2024. The winner will be notified via email using the contact information provided during entry. If the winner does not respond within seven (7) days of the notification, the Organizers reserve the right to select an alternate winner.
7. General Conditions
<ul>
<li>No purchase is necessary to enter or win.</li>
<li>The Contest is void where prohibited by law.</li>
<li>The prize does not include a presentation slot at NobleCon20.</li>
<li>By participating, entrants agree to be bound by these Terms and Conditions and the decisions of the Organizers, which are final and binding in all respects.</li>
<li>The Organizers reserve the right to disqualify any entry that is incomplete, misdirected, or in violation of these Terms and Conditions.</li>
</ul>
8. Privacy By entering the Contest, you agree that your personal information may be used by the Organizers in accordance with their privacy policies.
9. Limitation of Liability The Organizers are not responsible for any incorrect or inaccurate information, technical failures, or unauthorized intervention in the Contest. The Organizers are not liable for any injury or damage to persons or property resulting from participation in the Contest or acceptance or use of any prize.
10. Contact Information For questions or further information about the Contest, please contact the Organizers at contact@channelchek.com.

NobleCon20 VIP Contest Terms

NobleCon20 VIP Giveaway

Show form on click button

<h3 style="text-align: center;">Enjoying Channelchek?</h3>
There&#8217;s more to explore!
<a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research, 
Exclusive Videos, Live Event Updates, and more!
It&#8217;s absolutely free to join.
<a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" srcset="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg 300w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1024x876.jpg 1024w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-768x657.jpg 768w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1536x1314.jpg 1536w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-2048x1752.jpg 2048w" sizes="auto, (max-width: 351px) 100vw, 351px" /></a>
<script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script>